Humacyte Overview
Compare Humacyte's DCF valuation ($-0.11) to today's market price.
Get informed when a big investor buys or sells
+ Follow$-0.11
Overvalued by 118.8% based on the discounted cash flow analysis.
Humacyte (HUMA) currently reports a DCF fair value of $-0.11. Use the charts on this page to explore Humacyte's DCF fair value history and peer comparisons.
Humacyte's discounted cash flow (DCF) fair value estimate is $-0.11, about 118.8% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-0.11, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Humacyte, and consider following HUMA for alerts when major investors trade the stock.
Humacyte is classified in the Healthcare sector. On DCF fair value, it currently shows $-0.11. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HUMA with unrelated industries.
